

--21. The prosthetic heart valve of claim 14 wherein the substrate comprises tissue.

22. The prosthetic heart valve of claim 21 wherein said tissue comprises uncrosslinked tissue.

23. The prosthetic heart valve of claim 21 wherein said tissue comprises crosslinked tissue.

24. The prosthetic heart valve of claim 14 wherein the substrate comprises a synthetic polymer.

B3
July 19 23
~~25. A prosthesis comprising crosslinked tissue having a polypeptide growth factor associated therewith.~~

26. The prosthesis of claim 25 wherein said polypeptide growth factor comprises vascular endothelial growth factor.

27. The prosthesis of claim 25 wherein said crosslinked tissue comprises a crosslinked heart valve.

28. The prosthesis of claim 25 wherein said crosslinking involves glutaraldehyde moieties.--

REMARKS

Claims 1-11, 14, 15 and 21-28 remain for consideration. Claims 12 and 13 are canceled without prejudice in view of the restriction requirement. Claims 1, 14 and 15 have been amended to more particularly point out Applicants' claimed invention. The amendment to claim 1 is supported by Applicants' specification, for example, at page 13, lines 15-28 and page 14, lines 8-19. The amendment to claim 14 is supported by Applicants' specification, for example, at page 12, lines 17-30, page 13, lines 15-28 and page 14, lines 8-19. The amendment to claim 15 is supported by the specification, for example, at page 7, lines 14-16.

New claim 21 is supported by Applicants' specification, for example, at page 7, lines 14-30. New claims 22 and 23 are supported by Applicants' specification, for example, at page 4, lines 19-20. New claim 24 is supported by Applicants' specification, for example, from page 7, line 31 to page 8, line 11 and at page 8, lines 24-31. New claims 25 and 26 are supported by